CONGRESS NEWS

Presidential symposium EBMT 2022

BJH - volume 13, issue 4, june 2022

A. Enguita PhD, T. Feys MBA, MSc

SUMMARY

During the presidential symposium of the 48th Annual Meeting of the EBMT (2022), the Van Bekkum Award and seven top clinical abstracts were discussed. These presentations will be covered in this report.

(BELG J HEMATOL 2022;13(4):169–73)

Read more

Highlights from EAHAD 2022

BJH - volume 13, issue 3, may 2022

T. Feys MBA, MSc

SUMMARY

From 1–4 February 2022, more than 2,300 delegates joined and interacted online during the 2022 European Association for Haemophilia and Allied Disorders (EAHAD) Virtual Congress. During these days, EAHAD 2022 was once again the virtual ‘place-to-be’ for the latest in the field of haemophilia and allied disorders.

(BELG J HEMATOL 2022;13(3):133–6)

Read more

18th International Myeloma Workshop 2021

BJH - volume 13, issue 2, march 2022

N. Kint MD, PhD, R. Schots MD, PhD, W. De Brouwer MD

SUMMARY

The diagnostic and therapeutic landscape of multiple myeloma (MM) has been in constant evolution, resulting in many novel treatment opportunities for patients with MM, though many challenges remain in providing optimal care for patients with MM. In this article, several recent updates with regard to the diagnosis and treatment of MM, as presented at the 18th International Myeloma Workshop (IMW), have been summarised. In this summary, two main topics have been highlighted: 1) early treatment of high-risk smouldering MM, in combination with the development of non-invasive methods for risk stratification of smouldering MM, using circulating tumour cells and 2) updates on trials regarding novel treatment modalities, including novel combination regimens in newly diagnosed and relapsed MM patients, as well as novel immune therapies, with a focus on CAR-T cell therapy and bispecific antibodies.

(BELG J HEMATOL 2022;13(2):95–9)

Read more

Highlights of the 16th International Conference on Malignant Lymphoma

BJH - volume 12, issue 8, december 2021

K. Saevels MD

SUMMARY

This report summarises some useful studies presented during the 2021 International Conference on Malignant Lymphoma (ICML, virtual, June 18–22).

(BELG J HEMATOL 2021;12(8):355–60)

Read more

Highlights in chronic lymphocytic leukaemia

BJH - volume 12, issue 5, september 2021

D. Bron MD, PhD

(BELG J HEMATOL 2021;12(5):183-8)

Read more

Highlights in red blood cell disorders

BJH - volume 12, issue 5, september 2021

A. Van De Velde MD

SUMMARY

Insightful research into both sickle cell disease (SCD) and beta-thalassemia was presented at EHA 2021. Firstly, an overview of the worldwide mortality and morbidity of SCD was presented, which highlighted the treatment advances of the past twenty years, as well as the emerging co-morbidities that arise as SCD patients live longer. In this regard, SCD-associated cognitive dysfunction that arises from neurovascular complications were detailed, and the YEARS pulmonary embolism (PE) clinical decision algorithm was evaluated in SCD patients. Additionally, a phase II, double-blind, placebo-controlled study of luspatercept highlighted the drug’s ability to induce a clinically meaningful increase in Haemoglobin (Hb) in non-transfusion dependent beta-thalassemia.

(BELG J HEMATOL 2021;12(5):189-94)

Read more

AML and MDS: a virtual experience of real world data

BJH - volume 12, issue 5, september 2021

B. Heyrman MD

INTRODUCTION

The general poor prognosis of AML has stimulated the haematology society and industry to move forward in recent years. Because of these efforts, you could easily imagine yourself at a myeloma session during EHA2021. For patients non-eligible for intensive chemotherapy, the therapeutic arsenal has never been so wide and is constantly expanding. In Belgium, haematologists are bound to strict regulations making ‘game-changing’ data scarce at international congresses. However, the experts in the field shared their strategies in daily practice, which might be even more useful. Nevertheless, one rule remains that it is our duty to include patients in clinical trials whenever possible.

(BELG J HEMATOL 2021;12(5):197-200)

Read more
X